Shenzhen Bioeasy Biotechnology Co. Ltd. (SHE:300942) — Market Cap & Net Worth
Market Cap & Net Worth: Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)
Shenzhen Bioeasy Biotechnology Co. Ltd. (SHE:300942) has a market capitalization of $380.55 Million (CN¥2.60 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #13779 globally and #4133 in its home market, demonstrating a 0.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shenzhen Bioeasy Biotechnology Co. Ltd.'s stock price CN¥6.42 by its total outstanding shares 405077895 (405.08 Million). Also see Shenzhen Bioeasy Biotechnology Co. Ltd. total assets for a full breakdown of the balance sheet.
Shenzhen Bioeasy Biotechnology Co. Ltd. Market Cap History: 2021 to 2026
Shenzhen Bioeasy Biotechnology Co. Ltd.'s market capitalization history from 2021 to 2026. Data shows change from $1.69 Billion to $380.55 Million (-26.29% CAGR). Also see Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) cash flow conversion for how efficiently the company converts equity into cash flow.
Shenzhen Bioeasy Biotechnology Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shenzhen Bioeasy Biotechnology Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 300942 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.12x
Shenzhen Bioeasy Biotechnology Co. Ltd.'s market cap is 2.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
40.59x
Shenzhen Bioeasy Biotechnology Co. Ltd.'s market cap is 40.59 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.69 Billion | $597.54 Million | $236.51 Million | 2.83x | 7.14x |
| 2022 | $1.01 Billion | $686.90 Million | $82.97 Million | 1.48x | 12.23x |
| 2023 | $692.93 Million | $254.11 Million | -$184.91 Million | 2.73x | N/A |
| 2024 | $507.99 Million | $224.25 Million | $17.12 Million | 2.27x | 29.68x |
| 2025 | $557.78 Million | $263.23 Million | $13.74 Million | 2.12x | 40.59x |
Competitor Companies of 300942 by Market Capitalization
Companies near Shenzhen Bioeasy Biotechnology Co. Ltd. in the global market cap rankings as of September 19, 2026. Review 300942 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Shenzhen Bioeasy Biotechnology Co. Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Shenzhen Bioeasy Biotechnology Co. Ltd. Historical Marketcap From 2021 to 2026
Between 2021 and today, Shenzhen Bioeasy Biotechnology Co. Ltd.'s market cap moved from $1.69 Billion to $ 380.55 Million, with a yearly change of -26.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥380.55 Million | -31.77% |
| 2025 | CN¥557.78 Million | +9.80% |
| 2024 | CN¥507.99 Million | -26.69% |
| 2023 | CN¥692.93 Million | -31.69% |
| 2022 | CN¥1.01 Billion | -39.94% |
| 2021 | CN¥1.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Shenzhen Bioeasy Biotechnology Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $380.55 Million USD |
| MoneyControl | $380.55 Million USD |
| MarketWatch | $380.55 Million USD |
| marketcap.company | $380.55 Million USD |
| Reuters | $380.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shenzhen Bioeasy Biotechnology Co. Ltd.
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food testing reagents and instruments in China and internationally. The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatm… Read more